TAKOMA PARK, Md.--(BUSINESS WIRE)-- US Patent Innovations, LLC (USPI) a private biomedical technology, research and development company, announced today that it has secured the rights to develop a technology that selectively eradicates cancer in vitro without damaging normal cells. USPI entered into a technology transfer agreement with George Washington University (Washington, D.C.) and Johns Hopkins University (Baltimore, MD). Under the agreement, the two universities assigned their patent rights encompassing cold plasma, a technology that selectively kills cancer cells. Research results have shown that the application of cold plasma therapy selectively eradicates cancer cells in vitro without damaging normal cells and significantly reduces tumor size in vivo.
